A group of charities have announced $3 million in grants to fund four innovative research projects over two years, stemming from the 2026 Tauopathy Challenge Workshop. The Rainwater Charitable Foundation, in collaboration with the Alzheimer’s Association, the Aging Mind Foundation, and CurePSP, will fund the proposals based… Read More
The Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator (DxA) and The Michael J. Fox Foundation (MJFF) have announced a new US$5 million partnership to accelerate the development of minimally invasive biomarkers for measuring pathologies associated with Parkinson’s and Alzheimer’s diseases. Isobel Coleman, Chief Executive Officer of the Alzheimer’s Drug Discovery… Read More
Herantis is set to advance the clinical development of its Alzheimer’s therapy following a positive meeting with the US Food and Drug Administration (FDA). The company reports it completed a pre-IND meeting with the FDA to discuss the planned clinical development of HER-096, a first-in-class small peptide being developed to… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a UK group accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere,… Read More
Susan Abushakra, MD, Chief Medical Officer at Alzheon, discusses the validity of the amyloid hypothesis in light of the recent Cochrane review that found no clinical benefit of anti-amyloid monoclonal antibodies. A Cochrane systematic review published in April 2026 by Nonino, et al. – examining 17 randomised… Read More
News round-up for 25–29 May by Bruno Quinney, Content Team at DDW. This week, a UK group has accelerated efforts to develop a vaccine for Ebolavirus. Elsewhere, significant findings in colorectal and brain cancer could shape future cancer treatments. The top stories: UK group steps… Read More
Research into the use of peptide ‘shuttles’ has been praised for its potential to overcome barriers in Alzheimer’s and dementia treatment. Peter Davies, Deputy Director at the Texas A&M Health Institute of Biosciences and Technology, and his colleagues have been awarded a Dementia and Alzheimer’s Initiative (DARI)… Read More
The first patient has been dosed with a treatment for agitation in patients with Alzheimer’s disease (AD) dementia. The Phase II/III SERENADA trial is evaluating the efficacy and safety of Deraphan, developed by biopharmaceutical company Exciva. Deraphan is a combination of two clinically validated products: dextromethorphan, an NMDA… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Eli… Read More
News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW. This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration. The top stories: … Read More
Biopharmaceutical company AC Immune has reached an amended agreement with Eli Lilly for the development of an Alzheimer’s treatment. The amendment to the 2018 license includes an agreement on the collaboration to research and develop Tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD)… Read More
The first patient has been dosed in Alzheon’s Phase I trial of its Alzheimer’s drug. The biopharmaceutical company dosed the patient in ALZ-507, a novel investigational oral drug candidate. The drug has been developed to target upstream amyloid aggregation and inhibit the formation of neurotoxic soluble amyloid… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, there were crucial developments in neuroscience drug discovery. Elsewhere, a new treatment for… Read More
Developers of an AI-powered ‘co-scientist’ have been awarded the $1 million Alzheimer’s Insights AI Prize. Mount Sinai scientists, led by Dr Kuan-lin Huang, won the prize for developing Biomni-AD, an advanced AI-powered ‘co-scientist’ designed to dramatically reduce the time required to generate scientific insights from complex biomedical data. Biomni-AD… Read More
Eli Lilly’s appeal against guidance which did not recommend donanemab has been upheld, forcing authorities to reconsider the drug for NHS use. The National Institute for Health and Care Excellence (NICE) published the outcome for Lilly’s appeal, after final draft guidance had not recommended NHS reimbursement of donanemab for the treatment of mild cognitive… Read More
The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research on the brain proved a popular theme, unlocking insights into Alzheimer’s, dementia… Read More
